Difference between revisions of "Vortioxetine-duloxetine"
From Psychiatrienet
| Line 11: | Line 11: | ||
| info = | | info = | ||
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary. | * Occurrence of serotonin syndrome is theoretically possible, so caution is necessary. | ||
| − | * Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>}} | + | * Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref> |
| + | {{review}} | ||
| + | }} | ||
Revision as of 08:51, 4 November 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from vortioxetine to duloxetine.[1] [2]
Stop vortioxetine - Day 1: reduce dosage of vortioxetine to 5 mg/day.
- Day 8: stop administration of vortioxetine.
Start duloxetine- Day 8-14: a wash-out period of 1 week is necessary.
- Day 15: start administration of duloxetine in a dosage of 30 mg/day.
- Day 22: bloodlevel vortioxetine is now zero, so you can increase faster.
More information- Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
- Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.[3]
- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ European Medicines Agency | SmPC Brintellix 5 mg.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
